Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Ocular Therapeutix is supported by a clearer competitive setup after EyePoint’s LUCIA miss, which removes the most direct TKI implant rival for wet AMD and leaves AXPAXLI as the only remaining sustained-release “maintenance” therapy in that niche. Management’s 4Q26 NDA submission remains on track under the single-trial 505(b)(2) pathway, with pre-NDA minutes already in hand, a highly significant SOL-1 result (p=0.0006), no expected AdCom, and runway into 2028, reducing financing and regulatory risk. The company’s thesis is strengthened by a differentiated hydrogel platform, potentially 9-12 month dosing, and evidence that even competing programs validate physician demand for lowering treatment burden while AXPAXLI offers continuous intraocular VEGF suppression.

Ocular Therapeutix is burdened by a highly concentrated thesis on Axpaxli, a Phase 3 asset for wet AMD and NPDR, so any clinical setback, unexpected safety issue, or FDA request for more data could materially impair the company’s prospects. Although Ocular reported positive Phase 3 SOL-1 data, approval still depends on the adequacy of the NDA package, and commercialization faces stiff competition from larger anti-VEGF players, reimbursement uncertainty, and physician acceptance risk. Financially, the company has one revenue-generating product but has incurred significant losses since inception and will likely need substantial additional capital or partnerships to fund development, increasing dilution and execution risk.